StreetInsider.com News Articles

Fate Therapeutics to present FT819 CAR T-cell data at CCR-West

Wed, 09 Sep 2026 07:01:35 -0400

Fate Therapeutics, Inc. (NASDAQ: FATE) announced it will present clinical data from its off-the-shelf anti-CD19 CAR T-cell product candidate FT819 at the Congress of Clinical Rheumatology West meeting in Huntington Beach, California, scheduled for September 17-20, 2026.

The presentation, set for September 18, 2026, covers encore clinical data from the systemic lupus erythematosus arm of an ongoing Phase 1 trial. The data includes safety, efficacy, and translational results from 16 SLE patients treated in Regimen A, which evaluates a single dose of FT819 combined with fludarabine-free conditioning chemotherapy. Of those 16 patients, 13 completed at least one month of follow-up as

Fate Therapeutics to present FT819 CAR T-cell data at CCR-West

Wed, 09 Sep 2026 07:01:35 -0400

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

Wed, 09 Sep 2026 07:00:00 -0400

SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced clinical data from its off-the-shelf anti-CD19 CAR T-cell product candidate FT819, and pre-clinical data from its off-the-shelf anti-CD19 and CD38 CAR T-cell product candidate FT839 will be featured at the Congress of Clinical Rheumatology West (CCR – West) meeting, being held in Huntington Beach, CA on September 17-20, 2026.

The Company is presenting encore clinical data from

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

Wed, 09 Sep 2026 07:00:00 -0400

The Company is presenting encore clinical data from

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

Thu, 03 Sep 2026 07:00:00 -0400

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference, being held September 9–12, 2026 in New York, NY. Discussion topics will include an overview of the differentiated and favorable tolerability and meaningful clinical activity seen with FT819, the Company’s off-the-shelf CAR T-cell product candidate for the treatment of various autoimmune diseases.

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

Thu, 03 Sep 2026 07:00:00 -0400

Fate Therapeutics (FATE) PT Raised to $3.50 at Wells Fargo

Fri, 14 Aug 2026 08:52:11 -0400

Wells Fargo analyst Yanan Zhu raised the price target on Fate Therapeutics (NASDAQ: FATE) to $3.50 (from $2.50) while maintaining a Equal Weight rating.

Fate Therapeutics (FATE) PT Raised to $8 at Piper Sandler

Fri, 14 Aug 2026 08:26:23 -0400

Piper Sandler analyst Edward Tenthoff raised the price target on Fate Therapeutics (NASDAQ: FATE) to $8.00 (from $6.00) while maintaining a Overweight rating.

Fate Therapeutics starts Phase 2 lupus nephritis trial of FT819

Fri, 14 Aug 2026 07:00:47 -0400

Fate Therapeutics, Inc. (NASDAQ: FATE) has dosed the first patient in RECLAIM-LN (NCT07570862), a Phase 2 potentially registrational clinical trial evaluating FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, according to a press release from the company.

The first patient was treated in an outpatient setting and discharged the same day. Multiple patients are in the process of screening at several activated sites. The study is expected to enroll approximately 53 patients who are refractory to at least two prior systemic immunosuppressive therapies, with enrollment anticipated to complete within 15 to 18 months, by the first

Fate Therapeutics starts Phase 2 lupus nephritis trial of FT819

Fri, 14 Aug 2026 07:00:47 -0400

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fri, 14 Aug 2026 07:00:00 -0400

First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites

Trial advances FT819 toward a potential accelerated regulatory pathway supported by RMAT designation and participation in the FDA CMC Development and Readiness Pilot program

Study expected to enroll approximately 53 patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with Class III or IV lupus nephritis; study anticipated to complete enrollment in 15-18 months, by 1H2028

Patients to receive a single 900 million-cell dose of off-the-shelf FT819 following less-intensive conditioning with bendamustine;

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fri, 14 Aug 2026 07:00:00 -0400

First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites

Trial advances FT819 toward a potential accelerated regulatory pathway supported by RMAT designation and participation in the FDA CMC Development and Readiness Pilot program

Study expected to enroll approximately 53 patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with Class III or IV lupus nephritis; study anticipated to complete enrollment in 15-18 months, by 1H2028

Patients to receive a single 900 million-cell dose of off-the-shelf FT819 following less-intensive conditioning with bendamustine;

Form S-8 FATE THERAPEUTICS INC

Thu, 13 Aug 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260813/26920906.html

Form S-8 FATE THERAPEUTICS INC

Thu, 13 Aug 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260813/26920906.html

Form 10-Q FATE THERAPEUTICS INC For: Jun 30

Thu, 13 Aug 2026 08:34:00 -0400
si-local-file:///var/storage/secattach/20260813/26917142.html

Form 10-Q FATE THERAPEUTICS INC For: Jun 30

Thu, 13 Aug 2026 08:34:00 -0400
si-local-file:///var/storage/secattach/20260813/26917142.html

Form 8-K FATE THERAPEUTICS INC For: Aug 13

Thu, 13 Aug 2026 08:32:00 -0400
si-local-file:///var/storage/secattach/20260813/26917127.html

Form 8-K FATE THERAPEUTICS INC For: Aug 13

Thu, 13 Aug 2026 08:32:00 -0400
si-local-file:///var/storage/secattach/20260813/26917127.html

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Thu, 13 Aug 2026 08:30:00 -0400

First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge

FDA clearance of the FT839 IND application advances the Company’s novel dual CD19/CD38 targeting off-the-shelf CAR T-cell product candidate into a Phase 1/2 basket trial in autoimmune disease

Preliminary clinical data in SSc presented at the ISSCR 2026 Annual Meeting demonstrate rCRISS25 or greater responses and improvement in mRSS in all four treated patients, with no CRS, ICANS, GvHD, or hypogammaglobulinemia reported

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Thu, 13 Aug 2026 08:30:00 -0400

First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge

FDA clearance of the FT839 IND application advances the Company’s novel dual CD19/CD38 targeting off-the-shelf CAR T-cell product candidate into a Phase 1/2 basket trial in autoimmune disease

Preliminary clinical data in SSc presented at the ISSCR 2026 Annual Meeting demonstrate rCRISS25 or greater responses and improvement in mRSS in all four treated patients, with no CRS, ICANS, GvHD, or hypogammaglobulinemia reported

Form 4 FATE THERAPEUTICS INC For: Aug 04 Filed by: TAHL CINDY

Wed, 05 Aug 2026 16:04:00 -0400
si-local-file:///var/storage/secattach/20260805/26873728.html

Form 4 FATE THERAPEUTICS INC For: Aug 04 Filed by: TAHL CINDY

Wed, 05 Aug 2026 16:04:00 -0400
si-local-file:///var/storage/secattach/20260805/26873728.html

Form 4 FATE THERAPEUTICS INC For: Aug 04 Filed by: Valamehr Bahram

Wed, 05 Aug 2026 16:02:00 -0400
si-local-file:///var/storage/secattach/20260805/26873641.html

Form 4 FATE THERAPEUTICS INC For: Aug 04 Filed by: Valamehr Bahram

Wed, 05 Aug 2026 16:02:00 -0400
si-local-file:///var/storage/secattach/20260805/26873641.html

Form 144 FATE THERAPEUTICS INC Filed by: TAHL CINDY

Tue, 04 Aug 2026 16:40:00 -0400
si-local-file:///var/storage/secattach/20260804/26867285.html